Cellectar Reports Positive Trial Data for Cancer Drug
The company reported high response rates for its targeted radiation therapy in patients with Waldenström macroglobulinemia.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Should the FDA accelerate approval for new cancer drugs that show promise in clinical trials?
Cellectar Biosciences has released promising Phase 2b clinical trial results for its targeted radiation therapy, iopofosine I 131. The treatment showed significant efficacy in patients who had previously undergone BTK inhibitor therapy.
Why it matters
Patients suffering from this rare disease in a post-BTK inhibitor setting currently face a lack of effective treatment options and persistent refractory disease. This targeted approach offers a potential new pathway for those who have exhausted standard lines of therapy.
The clinical trial subgroup of 24 patients demonstrated an 87.5% overall response rate and a 100% clinical benefit rate. Median duration of response reached 16 months, with treatment-free survival observed at 19.1 months.
The players
Cellectar Biosciences
This Florham Park, N.J.-based pharmaceutical company focuses on the development of targeted radiation therapies for the treatment of cancer.
The details
Iopofosine I 131 utilizes targeted radiation that functions independently of the BTK pathway, providing an alternative for refractory cases. The drug is administered in a fixed course, with treatment-emergent adverse events occurring in fewer than 10% of the patient group.
Timeline
October 14-16, 2026: The International Workshop for Waldenström Macroglobulinemia takes place.
First quarter of 2027: Cellectar Biosciences expects to dose the first patients in a Phase 3 trial.
First half of 2027: The company plans to submit a New Drug Application to the FDA.
Health Landscape
This development represents a significant advancement in the study of targeted radiation therapy for Waldenström macroglobulinemia. It marks a shift away from traditional BTK-dependent pathways, potentially offering a more effective long-term solution for refractory cases.
This trial success provides a potential future treatment option for patients who have found current therapies ineffective. If the subsequent Phase 3 trial confirms these results, patients could gain access to a targeted therapy that offers an extended duration of response.
The takeaway
Targeted radiation therapy shows promise as a mechanism to treat patients who have failed to respond to conventional BTK inhibitors. Ongoing clinical trials will determine if these early-stage success rates can be replicated in larger, more diverse populations.
What happens next
Cellectar Biosciences is scheduled to initiate dosing for the first patients in a Phase 3 clinical trial during the first quarter of 2027. Subsequently, the company intends to submit a New Drug Application for accelerated approval to the FDA in the first half of 2027.
Further reading
For more information on current developments in oncology, visit the Cancer section.
More information
To learn more about the company's research pipeline, visit the Cellectar Biosciences company information page.
Live Poll
Should the FDA accelerate approval for new cancer drugs that show promise in clinical trials?
